1425 results
Thumbnail

D2.378 - Evaluations of Safety Margins and Response to Deucrictibant Extended-Release (XR) Tablet in Combination with Deucrictibant Immediate-Release (IR) Capsule

Thumbnail

D2.383 - Ocular Cicatricial Pemphigoid: Experience with Methotrexate immunosuppression in a case series from Mar del Plata, Argentina

Thumbnail

D2.395 - Erdosteine-induced multifocal fied drug eruption: a case series of five patients

Thumbnail

D2.399 - Successful Deferasirox Desensitization in a Patient with Delayed-Type Hypersensitivity

Thumbnail

D2.402 - Latex Sensitization as a Risk Factor for Perioperative Hypersensitivity Reactions in Asthmatic Children

Thumbnail

D2.41 - Production of recombinant Cuc ma 5: A Step Towards Molecular Diagnosis of Pumpkin Seed Allergy

Thumbnail

D2.413 - Diagnostic Value of the Basophil Degranulation Test in High-Risk Drug-Induced Anaphylaxis

Thumbnail

D2.415 - DRESS Syndrome induced by Lenalidomide

Thumbnail

D2.42 - Evaluation of User Experience with a Skin Prick Automated Test (SPAT) Device compared to a Manual Skin Prick Test (SPT) in Pediatric Patients

Thumbnail

D2.449 - Patients with Inadequately Controlled CRSwNP and Blood Eosinophil Count ≥150 cells/µL Experience Benefit with Depemokimab: An Analysis of Data from the Integrated ANCHOR-1/-2 Studies

Thumbnail

D2.475 - Treatment delay and likelihood of remission on omalizumab in chronic spontaneous urticaria: a real-world observational study

Thumbnail

D2.480 - Features of the molecular sensitization profile in children with autism spectrum disorder

Thumbnail

D2.490 - Consistent efficacy of a seasonal 300IR birch pollen sublingual immunotherapy in children and adolescents during worst pollen exposure: results of the YOBI trial

Thumbnail

D2.491 - Efficacy of a 300IR birch liquid sublingual immunotherapy during the alder and hazel pollen seasons: results of the YOBI trial

Thumbnail

D2.492 - Efficacy and safety of a 300IR daily dose of a SLIT of birch pollen allergen extract in children and adolescents with allergic rhinoconjunctivitis: results from the YOBI trial

Thumbnail

D2.494 - Tralokinumab treatment in adults with atopic dermatitis who were previously treated with dupilumab: 12-months real-world data from the TRACE study

Thumbnail

D2.496 - First-in-Human Phase I Clinical Outcomes of BxC-I17e Enriched with HSP70/miR-22-3p in Atopic Dermatitis

Thumbnail

D2.497 - Oral Deucrictibant Immediate-Release Capsule for On-Demand Treatment of Hereditary Angioedema Attacks: Results of the Phase 3 RAPIDe-3 Trial

Thumbnail

D2.498 - Berotralstat Decreased HAE Attacks Treated with On-Demand Therapy or Utilizing Professional Care in Pediatric Patients Aged 2 to

Thumbnail

D2.521 - Reshaping Allergy Assessment Pathways In The United Kingdom: Modeling System-Level Gains Through Discrete Event Simulation